Biotech Startups

VIAN Therapeutics develops a topical eye drop treatment for retinal diseases caused by angiogenesis and vascular permeability, offering a non-invasive alternative to intravitreal injections. The lead candidate targets age-related macular degeneration and diabetic macular edema by inhibiting pro-angiogenic factors and inflammatory cytokines.

2 investors

Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections. The company focuses on infections with high prevalence and severe illness potential, serving patients with unmet treatment needs across multiple viral categories.

2 investors

Vigilant Biosciences develops diagnostic technology for early detection of oral cancer, with products aimed at dental practices and clinicians. Its lead system has received FDA Breakthrough Device Designation.

2 investors

Virion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.

2 investors

ViroCarb is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its leadership brings experience in early-stage biopharma, medical devices, and industrial R&D.

2 investors

Visano Theranostics develops PSMA-targeted nanobubble contrast agents that add real-time molecular imaging to standard ultrasound workflows for the diagnosis and treatment of prostate cancer. The company licensed nanobubble technologies from Case Western Reserve University and is focused on precision oncology for prostate cancer.

2 investors

VISEN Pharmaceuticals is a biopharmaceutical company focused on endocrine-related therapies, developing and commercializing treatments such as long-acting growth hormone and parathyroid hormone therapies. It is based in Shanghai, China, and is publicly listed (HK: 2561).

2 investors

2 investors

Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.

2 investors

Vitroscope develops products and solutions that combine scientific expertise with product development capabilities, supported by advisors from leading research institutions. The company focuses on immunology and cell models based on its advisory team's expertise.

2 investors

VIVEbiotech is a contract development and manufacturing organization (CDMO) specialized exclusively in lentiviral vectors for both ex vivo and in vivo administration, following EMA and FDA regulatory requirements. It serves biotech and pharmaceutical companies across the US, Europe, Asia, and Australia.

2 investors

Vivere is an early-stage biotech developing cancer therapies that use a bioengineering platform (based on UC Berkeley research) to activate the immune system against "cold" solid tumors through targeted delivery. It focuses on immuno-oncology and gene/viral vector engineering to treat difficult solid cancers.

2 investors

VIVUS is a pharmaceutical company developing and commercializing therapies for patients with serious medical conditions and life-limiting diseases. The company advances innovative treatments through clinical development and commercialization expertise.

2 investors

Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples. The company serves research and diagnostic laboratories in the life sciences and precision oncology fields.

2 investors

VO Health is developing a blood test based on multi-omics molecular signatures to measure biomarkers related to human healthspan, performance, adaptation, and recovery. Founded by physician-scientists, it partners with performance establishments, clinics, clubs, and universities and operates a CLIA laboratory and proprietary biobank.

2 investors

VQ Biomedical is developing a minimally-invasive intravascular catheter that delivers supplemental oxygen directly into the bloodstream of hospitalized patients with respiratory failure, providing gas exchange independent of the lungs. It is positioned as an alternative to mechanical ventilation and VV-ECMO in critical care settings.

2 investors

vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases. Its lead candidate, cadisegliatin, is a glucokinase activator in Phase 3 trials for treating type 1 diabetes.

2 investors

Vyne Therapeutics is a biopharmaceutical company developing treatments for Graves' disease and thyroid eye disease (TED). Its lead candidate is designed to block the interaction of autoantibodies with the TSH receptor to interrupt the disease mechanism.

2 investors

Waiv provides AI-powered digital pathology services for biopharma companies, offering co-development partnerships that span AI biomarker discovery, algorithm validation, SaMD development, regulatory strategy (CE-IVD/FDA), and companion diagnostic commercialization. Its tools support clinical trial patient screening, stratification, endpoint development, and lab adoption of precision oncology tests.

2 investors

Wake offers medicinal and psychedelic fungi therapy combined with genomics-based integration aimed at supporting human health and personal transformation. It operates in the health and wellness industry.

2 investors

Walking Fish Therapeutics develops cell therapies aimed at restoring health and function in patients. The company is a biotech focused on therapeutic development.

2 investors

BYOHM develops bioelectrochemical systems that extract hydrogen and biomethane from wastewater and organic waste, generating net energy positive treatment with up to 10x more energy output than input. The technology targets municipal and industrial wastewater treatment operators seeking to reduce energy costs and recover valuable fuels.

2 investors

Watchfrog is an independent laboratory specializing in testing for endocrine-disrupting chemicals. It develops and offers alternative testing methods to replace animal studies, serving manufacturers across consumer goods, pharmaceutical, cosmetic, and food industries seeking to evaluate the safety and regulatory compliance of their ingredients, products, and packaging.

2 investors

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity. It operates in the biotech and RNA medicines industry.

2 investors